RealTime Dynamix™: Atopic Dermatitis US Q3
Atopic dermatitis (AD), the most common form of eczema affecting 5 to 20% of the worldwide population, is a chronic...
Atopic dermatitis (AD), the most common form of eczema affecting 5 to 20% of the worldwide population, is a chronic...
Despite an increasing user base, Cosentyx share has remained unchanged over the past six months, according to recently released data...
According to RealTime Dynamix™: Bone and Mineral Metabolism, a quarterly report published by Spherix Global Insights, the migration to non-calcium...
There are currently nine biologics, one biosimilar, and one oral janus kinase (JAK) inhibitor approved for the treatment of rheumatoid...
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), and Crohn’s Disease (CD) currently affects the lives of approximately 1.6 million Americans....
Despite Kevzara’s aggressive pricing play, early launch metrics of the newest IL-6 inhibitor, indicate conservative uptake, according to Spherix Global...
According to recent data released from Spherix Global Insights, early US dermatologist’s views of Tremfya leave ground to be covered...
According to a new study published by Spherix Global Insights, close to half of the dialysis patients treated with phosphate...
The management of renal anemia in dialysis patients as well as in those with later stage chronic kidney disease is...
According a new report from Spherix Global Insights, biologic treatment of nr-axSpA is complicated by multiple factors resulting in a...
The Q2 edition of RealTime Dynamix™: Multiple Sclerosis finds that trial rates for Ocrevus are in-line with pre-launch estimates and...
Use of biologics in the management of axial spondyloarthropathies (axSpA) has become well established in psoriatic arthritis and ankylosing spondylitis...